Sign in

CIK 0000730272

  • Large accelerated filer

REPLIGEN CORP

Sign in to watch
Ticker
RGEN
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
042729386
Phone
+1 781-449-9560
Business address
41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM, MA, 02453
  1. 4 Shares withheld for taxes Chief Executive Officer gave up 3,273 shares (to pay taxes)
  2. 4 Shares withheld for taxes Chief Financial Officer gave up 682 shares (to pay taxes)
  3. 4 Shares withheld for taxes Senior VP, R&D gave up 458 shares (to pay taxes)
  4. 4 Shares withheld for taxes See Remarks gave up 452 shares (to pay taxes)
  5. 4 Open-market sale Chief Financial Officer sold 5,647 shares at $200.00 ($1,129,400)
  6. 4 Grant or award Director acquired 111 shares (grant or award)
  7. 3 Insider Initial Statement of Ownership
  8. 4 Open-market buy Director bought 625 shares at $175.02 ($109,388)
  9. 4 Open-market sale Chief Executive Officer sold 25,000 shares at $200.00 ($5,000,000)
  10. 4 Option exercise Chief Financial Officer acquired 466 shares (option exercise)
  11. 4 Open-market sale Director sold 775 shares at $227.17 ($176,057)
  12. 4 Open-market sale Chief Executive Officer sold 26,402 shares at an average $224.73 ($5,933,438)
  13. 4 Open-market sale Chief Financial Officer sold 6,698 shares at an average $252.86 ($1,693,689)
  14. 4 Open-market sale Senior VP, R&D sold 4,840 shares at an average $254.32 ($1,230,886)
  15. 4 Open-market sale See Remarks sold 3,357 shares at $243.01 ($815,785)
  16. 4 Open-market sale Chief Operating Officer sold 2,000 shares at $240.40 ($480,800)
  17. 4 Open-market sale Chief Financial Officer sold 2,000 shares at $220.00 ($440,000)
  18. 4 Open-market sale Chief Executive Officer sold 24,802 shares at $200.00 ($4,960,400)
  19. 4 Grant or award Director acquired 1,202 shares (grant or award)
  20. 4 Grant or award Director acquired 534 shares (grant or award)

Page 9 of 34 · 669 filings